Lenalidomide and Ranitidine hydrochloride drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lenalidomide (lenalidomide) and Ranitidine hydrochloride (ranitidine hydrochloride). Common drug interactions include local swelling among females and acute coronary syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Lenalidomide and Ranitidine hydrochloride. It is created by eHealthMe based on reports of 67 people who take the same drugs from the FDA, and is updated regularly.

What is Lenalidomide?

Lenalidomide has active ingredients of lenalidomide. eHealthMe is studying from 52,881 Lenalidomide users. Check the latest studies of Lenalidomide.

What is Ranitidine hydrochloride?

Ranitidine hydrochloride has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 76,413 Ranitidine hydrochloride users. Check the latest studies of Ranitidine hydrochloride.



On Jul, 13, 2026

67 people who take Lenalidomide and Ranitidine hydrochloride together, and have interactions are studied.

Lenalidomide and Ranitidine hydrochloride drug interactions.

What are the common drug interactions of Lenalidomide and Ranitidine Hydrochloride, by gender? *:

female:

  1. Local swelling (swelling at the site of some application of substance or injury)
  2. Lower limb fracture
  3. Lumbar vertebral fracture
  4. Lung infection
  5. Multiple myeloma (cancer of the plasma cells)
  6. Nasopharyngitis (inflammation of the nasopharynx)
  7. Neoplasm progression (growth of tumour)
  8. Pain in extremity
  9. Plasma cell myeloma (cancer that begins in plasma cells)
  10. Plasmacytoma (neoplasm of plasma cells (usually in bone marrow))

male:

  1. Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood)
  2. Aortic valve stenosis (narrowing of the aortic valve)
  3. Sepsis (a severe blood infection that can lead to organ failure and death)
  4. Vomiting
  5. Abdominal pain
  6. Arthritis reactive (autoimmune condition that develops in response to an infection in another part of the body)
  7. Infection
  8. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  9. Plasma cell myeloma (cancer that begins in plasma cells)
  10. Pulmonary embolism (blockage of the main artery of the lung)

What are the common drug interactions of Lenalidomide and Ranitidine Hydrochloride, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Pulmonary embolism (blockage of the main artery of the lung)

20-29:

n/a

30-39:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  2. Febrile neutropenia (fever with reduced white blood cells)
  3. Pneumonia

40-49:

n/a

50-59:

  1. Anxiety
  2. Catheter site infection (infection at the site of insertion)
  3. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  4. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  5. Dizziness
  6. Furuncle (infection of the hair follicle)
  7. Haemoglobin decreased
  8. Neutropenia (an abnormally low number of neutrophils)
  9. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  10. Staphylococcal bacteraemia (a bacterial infection of blood)

60+:

  1. Pneumonia
  2. Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood)
  3. Blood creatinine increased
  4. C-reactive protein decreased
  5. Cardiac arrest
  6. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  7. Death
  8. Nausea (feeling of having an urge to vomit)
  9. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  10. Plasma cell myeloma (cancer that begins in plasma cells)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 58 people, 86.57%
  2. Diarrhea: 4 people, 5.97%

* Approximation only. Some reports may have incomplete information.

Do you take Lenalidomide and Ranitidine hydrochloride?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lenalidomide and Ranitidine hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lenalidomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ranitidine hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lenalidomide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ranitidine hydrochloride and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide and ranitidine hydrochloride (the active ingredients of Lenalidomide and Ranitidine hydrochloride, respectively), and Lenalidomide and Ranitidine hydrochloride (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: